---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004131"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:03:09.649706+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics reports pipeline progress, ~$1B cash, and outlines milestones for 2023-2024

## Summary
- Estimated $1.0B cash, cash equivalents, and marketable securities as of Dec 31, 2022; cash runway expected into 2025.
- BEAM-101 (SCD): BEACON trial sentinel cohort enrollment completion and expansion cohort initiation expected in 2023; data from multiple patients in 2024.
- BEAM-201 (T-ALL/T-LL): FDA IND clearance; first patient dosing expected by mid-2023 in Phase 1/2 trial.
- BEAM-301 (GSDIa) regulatory submission planned by late 2023/early 2024; BEAM-302 (AATD) submission planned early 2024.
- North Carolina manufacturing facility expected to initiate GMP operations in late 2023.

## SEC filing metadata
- accession: 0001193125-23-004131
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312523004131/0001193125-23-004131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312523004131/d393225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004131
- JSON: https://secwatch.observer/filing/0001193125-23-004131.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.